Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1999

View Archived Issues

Company Profile: Cangene

Immunomedics seeks EMEA approval for CEA-Scan

Phase II study initiated by Neose for otitis media prevention

Inflazyme updates shareholders

Cell Genesys: Q4 and year-end 1998 highlights

Nicotinic acetylcholine receptor agonists emerge from Sumitomo R&D

SB patents new cathepsin K inhibitors

Novel triptolide derivatives from HMR for rheumatoid arthritis and other autoimmune diseases

Novel cognition-enhancing agents designed at MS&D

Orally active inhibitors of tumor neovascularization described by Mercian

Recently issued U.S. patent covers new D4 receptor ligands developed at Merck Sharp & Dohme

UPSA reveals potent, orally active and well-tolerated antiinflammatory/analgesic agents

OP-1 protects against cerebral infarct in rat model

Novel piperazine hydroxyethylamine HIV protease inhibitor shows promise in preclinical studies

Another lipid-lowering statin now on the market in Argentina

Structurally novel dimeric steroid with cytotoxic activity isolated from marine sponge

Digene reports advances in papillomavirus diagnosis

Small Molecule Therapeutics identifies antibacterial class of compounds

Deltagen enters another gene target validation collaboration

Shaman reviews filing strategy for SP-303 following pre-NDA meeting with FDA

OSI diagnostic subsidiary will develop test to detect childhood cancer

Three patents covering drug formulation technology issued to Delsys

Angiotech to study paclitaxel for yet another new indication

Anti-TNF MAb reduces circulating levels of sPLA2 in Crohn's disease patients

Carrington announces plans for phase III testing of Aliminase

Licensing opportunity from NIH: methods of treating inflammation

Dietary therapy of rheumatoid arthritis evaluated in six-month controlled trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...